Paul Snyder, Write2MarketOnce home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech.
Born from technology developed at the Albert Einstein College of Medicine, Greenville-based Zylö Therapeutics is utilizing the regional chemical/mechanical engineering expertise and support network to improve drug and nitric oxide delivery through a proprietary sustained delivery system called Nanopods. Formally founded in late 2017, the company secured exclusive, worldwide rights to the technology and is currently working to solve the chemical and manufacturing issues that will enable scale-up and commercialization.
Here’s how Zylö Therapeutics describes the technology: “The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. With our system, Zylö has harnessed the powerhouse therapeutic, nitric oxide, as well as other therapeutics that have bioavailability challenges.”
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.